Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients

Journal of Immunotherapy

Volumn 33, Issue 1, 2010, Pages 83-91

  Andrade Filho, Pedro A ^a   López Albaitero, Andrés ^a   Gooding, William ^b   Ferris, Robert L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

CTL; EGFR; Head and neck cancer

Indexed keywords

CANCER VACCINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; HLA A ANTIGEN; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; UBIQUITINATION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SEPARATION; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HLA-A ANTIGENS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; T-LYMPHOCYTES, CYTOTOXIC;

EID: 74349085544     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b8f421     Document Type: Article

References (39)

1. Cassidy J. Cetuximab for the treatment of patients with colorectal cancer. Nat Clin Pract Oncol. 2008;5:310-311.
2. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579-3584.
3. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-7356.
4. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18: 904-914.
5. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550-6565.
6. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002;29 (1 suppl 4):47-50.
7. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17-23.
8. Kim S, Grandis JR, Rinaldo A, et al. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck. 2008;30:667-674.
9. Valentini AM, Pirrelli M, Caruso ML. EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab? Curr Opin Mol Ther. 2008;10:124-131.
10. Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007;133:1277-1281.
11. Kawaguchi Y, Kono K, Mimura K, et al. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-ex-pressing esophageal squamous cell carcinoma. Int J Cancer. 2007;120:781-787.
12. Roda JM, Joshi T, Butcher JP, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res. 2007;13:6419-6428.
13. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007;13:1552-1561.
14. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic color-ectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007;25:3712-3718.
15. Lu Y, Li X, Liang K, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res. 2007;67:8240-8247.
16. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008;27:3944-3956.
17. Ferris RL, Buck C, Hammond SA, et al. Class I-restricted presentation of an HIV-1 gp41 epitope containing an N-linked glycosylation site. Implications for the mechanism of processing of viral envelope proteins. J Immunol. 1996;156:834-840.
18. Ferris RL, Hall C, Sipsas NV, et al. Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization. J Immunol. 1999;162:1324-1332.
19. Emens LA, Reilly RT, Jaffee EM. Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. Breast Dis. 2004;20:13-24.
20. Mittendorf EA, Storrer CE, Shriver CD, et al. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol. 2006;13: 1085-1098.
21. +chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol. 2008;26(suppl):6007. Abstract.
22. Heo DS, Snyderman C, Gollin SM, et al. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res. 1989;49: 5167-5175.
23. Lin CJ, Grandis JR, Carey TE, et al. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck. 2007;29:163-188.
24. Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and-B antigens in a mutant TxB cell hybrid. Embo J. 1986;5:943-949.
25. Parham PBC, Bodmer WF. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol. 1979;123:342-349.
26. Parham PBW. Monoclonal antibody to a human histocompat-ibility alloantigen, HLA-A2. Nature. 1978;276:397-399.
27. Wang X, Liang B, Rebmann V, et al. Specificity and functional characteristics of anti-HLA-A mAbs LGIII-147.4.1 and LGIII-220.6.2. Tissue Antigens. 2003;62:139-148.
28. Goldman JM, Hibbin J, Kearney L, et al. HLA-DR monoclonal antibodies inhibit the proliferation of normal and chronic granulocytic leukaemia myeloid progenitor cells. Br J Haematol. 1982;52:411-420.
29. Vitale M, Rezzani R, Rodella L, et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 1998;58:737-742.
30. Lopez-Albaitero A, Nayak JV, Ogino T, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 2006;176:3402-3409.
31. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-3142.
32. Gomez-Nunez M, Pinilla-Ibarz J, Dao T, et al. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leuk Res. 2006;30:1293-1298.
33. Rammensee H, Bachmann J, Emmerich NP, et al. SYF-PEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213-219.
34. Falk K, Rotzschke O, Stevanovic S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991;351:290-296.
35. Petersen TR, Buus S, Brunak S, et al. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol. 2001;53: 357-364.
36. Rotzschke O, Falk K. Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway. Immunol Today. 1991;12:447-455.
37. Deng Y, Yewdell JW, Eisenlohr LC, et al. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J Immunol. 1997;158: 1507-1515.
38. Morgan CL, Ruprai AK, Solache A, et al. The influence of exogenous peptide on beta2-microglobulin exchange in the HLA complex: analysis in real-time. Immunogenetics. 1998; 48:98-107.
39. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646-8654.